Menopausal Hormone Therapy in Women With CVD Risk or Stable CVD
abstract
This abstract is available on the publisher's site.
Access this abstract nowMenopausal hormone therapy (HT) was widely used in the past, but with the publication of seminal primary and secondary prevention trials that reported an excess cardiovascular risk with combined estrogen-progestin, HT use declined significantly. However, over the past 20 years, much has been learned about the relationship between the timing of HT use with respect to age and time since menopause, HT route of administration, and cardiovascular disease risk. Four leading medical societies recommend HT for the treatment of menopausal women with bothersome menopausal symptoms. In this context, this review, led by the American College of Cardiology Cardiovascular Disease in Women Committee, along with leading gynecologists, women's health internists, and endocrinologists, aims to provide guidance on HT use, including the selection of patients and HT formulation with a focus on caring for symptomatic women with cardiovascular disease risk.
Click on any of these tags to subscribe to Topic Alerts. Once subscribed, you can get a single, daily email any time PracticeUpdate publishes content on the topics that interest you.
Visit your Preferences and Settings section to Manage All Topic Alerts
Additional Info
Disclosure statements are available on the authors' profiles:
Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?
Circulation 2023 Feb 14;147(7)597-610, L Cho, AM Kaunitz, SS Faubion, SN Hayes, ES Lau, N Pristera, N Scott, JL Shifren, CL Shufelt, CA Stuenkel, KJ LindleyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.